Antibiotic lock therapy: review of technique and logistical challenges.

Antibiotic lock therapy (ALT) for the prevention and treatment of catheter-related bloodstream infections is a simple strategy in theory, yet its real-world application may be delayed or avoided due to technical questions and/or logistical challenges. This review focuses on these latter aspects of ALT, including preparation information for a variety of antibiotic lock solutions (ie, aminoglycosides, beta-lactams, fluoroquinolones, folate antagonists, glycopeptides, glycylcyclines, lipopeptides, oxazolidinones, polymyxins, and tetracyclines) and common clinical issues surrounding ALT administration. Detailed data regarding concentrations, additives, stability/compatibility, and dwell times are summarized. Logistical challenges such as lock preparation procedures, use of additives (eg, heparin, citrate, or ethylenediaminetetraacetic acid), timing of initiation and therapy duration, optimal dwell time and catheter accessibility, and risks of ALT are also described. Development of local protocols is recommended in order to avoid these potential barriers and encourage utilization of ALT where appropriate.

Introduction

The prevention and management of catheter-related bloodstream infections (CRBSI) is a significant health care challenge. CRBSI occur at an estimated rate of 41,000 infections in US hospitals annually.1 This rate varies based on factors such as hospital bed size, medical school affiliation of the hospital, and type of unit/facility (eg, burn critical care unit, inpatient medical ward, rehabilitation facility). In US medical and surgical units of any acuity level, the most recent data from 2012 estimate the mean incidence rate of CRBSI at 0.8 to 0.9 per 1,000 central line days.2 However, patients in both medical and surgical critical care units are at higher overall risk of developing CRBSI compared to similar patient populations in inpatient wards due to increased central venous catheter (CVC) utilization, averaging 0.35–0.59 central line days per 1 patient-day compared to only 0.15–0.17 in inpatient wards.2 Among critically ill patients, those in burn units or long-term care acute care hospitals are at particularly high risk of developing CRBSI (mean rates of 3.4 and 1.6 CRBSI per 1,000 central line days, respectively). While overall CRBSI rates appear to have decreased in the last 10–15 years,3 they remain a substantial source of morbidity and mortality in the health care system.

Clinical practice guidelines recommend antibiotic lock therapy (ALT) for both prevention and treatment of catheter-related infections (CRI).4,5 Guidelines from the Centers for Disease Control and Prevention recommend ALT as prophylaxis for patients with long-term catheters and a history of multiple CRI despite maximal efforts to follow aseptic technique.4 Guidelines from the Infectious Diseases Society of America (IDSA) for the diagnosis and management of CRI recommend antibiotic locks as adjunctive therapy specifically for catheter salvage in cases where the catheter is not removed.5 CVC removal remains first-line therapy for management of CRI, especially in cases of Staphylococcus aureus and resistant gram-negative pathogens, including Pseudomonas aeruginosa. Bustos et al have previously reviewed the diagnosis and treatment of CRI in detail.6 This review focuses on the technical aspects of ALT for prevention and treatment of CRBSI in particular, including solution preparation and logistical challenges regarding administration. Details regarding non-antibiotic lock solutions, including antiseptic agents (eg, ethanol) and antifungals, are not discussed in this review.

Antibiotic activity against biofilms

Intravascular catheters and other implanted medical devices routinely develop microbial biofilms on their inert surfaces. A biofilm is defined as a microbial community with cells attached to a substratum or each other and embedded in a matrix of extracellular polymeric substances (EPS), or glycocalyx. EPS density varies within the biofilm itself, appearing densest in deeper layers immediately surrounding the colonies of microorganisms. Its density decreases in more superficial layers, leading to the formation of water channels in and around the biofilm matrix.7 Such channels allow for the transfer of nutrients, waste products, quorum-sensing molecules, and other substances (including antibiotics), similar to the function of a circulatory system in a multicellular organism.

Biofilms represent a form of adaptive resistance resulting in a significant reduction of antibiotic susceptibility by ten-to 1,000-fold (based on minimal inhibitory concentrations [MIC]). The exact mechanisms of antibiotic resistance within biofilms remain unclear, yet a common hypothesis is subtherapeutic exposure of biofilm cells to antibiotics. Biofilms may slow the distribution of antibiotics via charge interaction, size exclusion, viscosity of the matrix, and possible adsorption to proteins. EPS may also inactivate antibiotic molecules prior to reaching biofilm cells. Table 1 summarizes the biofilm penetration of select antibiotics. The extent of penetration varies widely (range 0%–100%), being excellent with agents such as fluoroquinolones and rifamycins, variable with beta-lactams and vancomycin, and attenuated with aminoglycosides. This variability is likely due to the heterogeneity in biofilm composition, the physiochemical properties of antibiotics, and study design. Individual biofilms are a complex mixture of polysaccharides (eg, alginate), proteins, and DNA, with significant inter- and intra-species composition variability. Due to the high content of polyanionic substances, positively charged drugs (eg, aminoglycosides) may bind to EPS and exhibit a particularly attenuated distribution into biofilm.8 Differences in study methodology may also account for the wide range of observed penetration, including aspects such as the site (eg, edge or center of the biofilm) and timing (eg, 1, 6, 24, 72 hours, or continuously) of antibiotic concentration measurement. Further studies have suggested that not only the extent, but also the attenuated rate of antibiotic penetration may play a role in antibiotic resistance.9

Table 1

Summary of biofilm penetration for select antibiotics

Antibiotic class/agent	Microorganism	Extent of penetration	Rate of penetration	Reference
Fluoroquinolones
Ciprofloxacin	Bacillus cereus, Pseudomonas fluorescens	100%	NR	10
	Pseudomonas aeruginosa	100%	Rapid	74
	P. aeruginosa	25%–50%	Rapid	75
	Klebsiella pneumoniae	80%–100%	Rapid	11
	Staphylococcus aureus, Staphylococcus epidermidis	86%–100%	NR	76
Levofloxacin	P. aeruginosa	100%	Rapid	75
Rifamycins
Rifampin	S. epidermidis	79% to >90%	Rapid	77,78
Oxazolidinones
Linezolid	S. epidermidis	~100%a	Rapid	79
Lipopeptides
Daptomycin	S. epidermidis	≥100%b	Rapid	80
Tetracyclines
Tetracycline	B. cereus, P. fluorescens	88%–93%	NR	10
Macrolides
Erythromycin	B. cereus, P. fluorescens	72%–86%	NR	10
	S. epidermidis	45%–93%	Variable/slow	81
Beta-lactams
Ampicillin	K. pneumoniae (beta-lactamase positive)	0%	NA	11
	K. pneumoniae (beta-lactamase negative)	80%–100%	Rapid	11
Oxacillin	S. aureus, S. epidermidis	<70%	NR	76
Piperacillin	P. aeruginosa	50%–100%	Rapid	75
	P. aeruginosa	0%–15%	NR	82
Cefotaxime	S. aureus, S. epidermidis	68%–70%	NR	76
Imipenem	P. aeruginosa	50%–100%	Rapid	75
Glycopeptides
Vancomycin	S. aureus, S. epidermidis	<70%	NR	76
	S. epidermidis	Adequatec	Slow	77,83
	S. aureus	Adequateb,d	Slow	9
Aminoglycosides
Streptomycin	B. cereus, P. fluorescens	0%–60%	NR	10
Tobramycin	P. aeruginosa	40%	Slow	74
Gentamicin	P. aeruginosa	<25%	Slow	75
Amikacin	P. aeruginosa	<25%	Slow	75
	S. aureus, S. epidermidis	79%–98%	NR	76

Notes:

Comparable penetration compared to isolates of planktonic cells

measured as intensity of fluorescence using confocal microscopy or other methods

vancomycin concentrations reportedly exceeded the minimal inhibitory concentrations and minimal bactericidal concentrations for tested isolates

represents vancomycin concentrations from 15–45 μg/mL.

Abbreviations: NA, not applicable; NR, not reported.

Alterations in drug penetration are not the sole factor determining antibiotic resistance in biofilms. Biofilm cells are often inherently more resistant to antibiotics than planktonic cells. They may express additional resistance factors (increased efflux pumps, stress response regulons, inactivating enzymes) and exhibit a slower growth rate. Due to the growth-dependent mechanisms of action of most antibiotics, the killing effect is often diminished in these sessile biofilm cells. The multifactorial nature of biofilm resistance to antibiotics is well-illustrated by data suggesting biofilm penetration is unrelated to the ability of the antibiotic to disrupt biofilm or kill biofilm cells.10,11 One study showed ampicillin did not penetrate the biofilm of a wild-type strain of Klebsiella pneumoniae (0% penetration), but was able to rapidly penetrate the biofilm of a mutant K. pneumoniae strain where beta-lactamase activity was eliminated (80%–100% penetration).11 Even so, beta-lactamase–negative biofilm cells with adequate ampicillin exposure displayed resistance to ampicillin when compared to beta-lactamase–negative planktonic cells, suggesting poor penetration alone did not account for the observed resistance.11 Alternatively, streptomycin, an agent with poor biofilm penetration of 0%–60%, has exhibited comparable biofilm removal and killing (14%–17% and 15%–40%, respectively) as the readily penetrating agent, ciprofloxacin (100% penetration, 12%–23% removal, 14%–36% killing).10 Thus, the ideal antibiotic for treatment of biofilm should display adequate penetration into EPS as well as a potent activity against biofilm cells. The antimicrobial effect of potential additives, such as ion chelators like ethylenediaminetetraacetic acid (EDTA) and citrate, should also be considered. Such agents have been shown to disrupt biofilm and exhibit synergistic activity with antibiotics.12,13

Antibiotic lock solutions

In general, antibiotic lock solutions combine a highly concentrated antibiotic (100–1,000 times planktonic MIC) with an anticoagulant to allow for local instillation into the catheter lumen. The solution is allowed to dwell or is “locked” while the CVC is not in use to prevent colonization or sterilize a previously infected catheter. ALT is often utilized in clinical practice in a prophylactic modality to prevent luminal colonization and subsequent CRBSI. This practice has demonstrated significant benefit in hemodialysis-dependent patients and those with indwelling CVC for intravenous (IV) chemotherapy and total parenteral nutrition (TPN).5,14,15 ALT is also an option in the management of CRBSI as an adjunct to systemic antibiotics, increasing rates of catheter salvage.5,16 Although there is wide variability in clinical utilization of ALT among infectious diseases specialists, nearly 40% report attempting catheter salvage with ALT.17

Ideal lock solution

The ideal lock solution should possess a number of characteristics. Many, but perhaps not all, of these factors are applicable for both treatment and prophylactic modalities.

Spectrum of activity should include common or targeted pathogens. Although the majority of CRBSI are secondary to gram-positive organisms, protracted use of CVCs in high-risk patients increases the likelihood of gram-negative and fungal pathogens.

Ability to penetrate or disrupt a biofilm. Especially important in treatment, the ability to penetrate a biofilm and demonstrate activity against biofilm cells at concentrations 100–1,000 times standard concentrations is essential. Several lock solution additives, including ion chelators such as citrate and EDTA, can also disrupt intact biofilms.

Compatibility with anticoagulants. Not all CVC will require the addition of an anticoagulant (eg, heparin) to maintain patency; however, to decrease the risk of occlusion, the ability to include a low-dose heparin (eg, <1,000 units/mL) or an alternative ion chelator such as citrate will enhance the ability to broadly utilize a lock solution.

Prolonged stability. The ability to prepare lock solutions in bulk and apply extended expiration will enhance the continuation of ALT at points of transitions of care. This will be important for a pharmacy to maximize cost-effective use of lock therapy. Storage at room temperature as opposed to refrigeration is an additional advantage.

Low risk of toxicity and adverse events. The small volumes used in the intraluminal space do not lend themselves to high risk of toxicity. However, higher concentrations of specific agents (eg, aminoglycosides and citrate) have been associated with significant toxicity and should be avoided when using ALT.18,19 There is additional concern if these solutions are flushed as opposed to aspirated, which could expose the patient to higher concentrations of anticoagulants (eg, heparin). Ethanol at higher concentrations may be associated with minor adverse events, especially in low-weight neonates.14 Catheter occlusion is another possible adverse event with ALT, especially in the absence of a low-dose anticoagulant in solution.

Low potential for resistance. Although there is likely minimal systemic exposure of the antibiotic lock solution if aspirated with each exchange, use of agents with a low risk for development of resistance is important. In a treatment modality, if the systemic antibiotic is also used concurrently as a component of the lock solution, concern for resistance is diminished.

Cost-effectiveness. Use of certain agents (eg, linezolid, daptomycin) may be cost-prohibitive, especially when used on a larger population in a prophylactic modality. Careful consideration on maximizing compounding efficiency and stability should be done prior to initiating lock therapy with such high-cost agents.

Antibiotics in solution: stability and compatibility

Despite the variability in quality and quantity of data, many antibiotics have been investigated in lock solutions in both in vitro models and in clinical studies. Table 2 provides a detailed, referenced summary of the available data on antibiotic lock solutions. In vitro or animal data were included only when antibiotics were combined with an additive. In vivo data were included if a unique concentration of the lock solution was used. Comments on dwell time and duration of use are included when available for in vivo studies. Of note, many stability studies are conducted under varying conditions, including temperature (eg, 4°C vs 37°C), exposure duration, and storage conditions (eg, glass vs polyurethane catheter) and should be interpreted accordingly.

Table 2

Summary of available in vitro and in vivo data on antibiotic lock solutions

Antibiotic class/agent	Antibiotic concentrations	Additives and concentrations	Stability comments	Dwell time/duration (if applicable)	Type of investigation(s)
Penicillins
Penicillin G25	50,000 units/mL	Heparin 2,500 and 5,000 units/mL	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions; duration 2–3 weeks with systemic antibiotics	Case report
Ampicillin24, 84, 85	10 mg/mL	Heparin 10 and 5,000 units/mL	Physically stable (visual confirmation) for 14 days at 4°C and 37°C; yellow color reported at day 3; heparin stable for 14 days based on aPTT measures		In vitro bioactivity study
	5 mg/mL	No additives			Case report
	2 mg/mL	Heparin 10 units/mL	Visual confirmation of physical compatibility	Dwell time up to 6 hours, solution aspirated then replaced to target continuous lock	In vivo study
Amoxicillin25	5 mg/mL	Heparin 2,500 units/mL	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions; duration 2–3 weeks with systemic antibiotics	Single case report
Piperacillin24–26	10, 20, 40 mg/mL	Heparin 10 and 5,000 units/mL	Physically stable (visual confirmation) for 14 days at 4°C and 37°C; yellow color reported at day 3 with piperacillin 40 mg/mL; heparin stable for 14 days based on aPTT measures with piperacillin 40 mg/mL		In vitro bioactivity study
	100 mg/mL	Heparin 400 units/mL	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions; duration 2–3 weeks with systemic antibiotics	Case report
Piperacillin/tazobactam27	10 mg/mL	Heparin 100 units/mL	Visual confirmation of physical compatibility	Two case reports; dwell time of a minimum of 12 hours per day; duration of 10 days with systemic antibiotics
Ticarcillin/clavulanate23	0.5 mg/mL	Heparin 100 units/mL	Bioassay stability sampling confirmed < 10% loss of activity at 10 days at 25°C and 37°C in polystyrene test tubes; addition of susceptible bacteria had no impact on stability		In vitro bioassay stability study
Nafcillin86	83.3 mg/mL, 166.6 mg/mL	No additives	Visual confirmation of physical compatibility	Dwell time of 12 hours daily; average duration 8 days	Case series (6 reports)
Cloxacillin87	100 mg/mL	Heparin 1,000 units/mL	Visual confirmation of physical compatibility	Dwell time up to 96 hours between HD sessions	In vivo study
Mezlocillin88	2 mg/mL	No additives	Visual confirmation of physical compatibility	Dwell time 12–24 hours; duration 10–14 days	Case series (one report)
Flucloxacillin38	20 mg/mL	Heparin 10–10,000 units/mL	Visual precipitation testing grid; authors comment that “low-dose heparin” showed precipitation at 48 hours at 25°C and 37°C; combination with heparin 4,000 units/mL stable for 72 hours		In vitro bioactivity study
Cephalosporins
Cefazolin20,21,23,24,45,84,89–96	10 mg/mL	Heparin 10 and 5,000 units/mL	Physically stable (visual confirmation) for 14 days at 4°C; and 37°C; yellow color reported; heparin stable for 14 days based on aPTT measures		In vitro bioactivity study
	10 mg/mL	Heparin 5,000 units/mL	< 10% change in absorbance at 72 hours in glass tubes; 27.3% change in absorbance at 72 hours in polyurethane catheter		In vitro stability study
	5 mg/mL	Gentamicin 5 mg/mL and heparin 1,000 and 5,000 units/mL	Visual confirmation of physical compatibility; combination with heparin 5,000 units/mL confirmed to 72 hours at 37°C – a haze reported when prepared at room temperature within 30 minutes		In vivo study; in vitro model of CRSBI
	5 mg/mL	TPA 1 mg/mL	Visual confirmation of physical compatibility up to 48 hours		In vivo study
	5 mg/mL	Heparin 5,000 units/mL	Visual confirmation of physical compatibility up to 72 hours	Dwell time up to 72 hours between HD sessions; duration up to 2 weeks	In vitro and animal models of CRBSI; in vivo study
	5 mg/mL	Gentamicin 1 mg/mL and heparin 2,500 units/mL	Visual confirmation of physical compatibility up to 72 hours at 25°C and 37°C	Dwell time up to 72 hours between HD sessions	In vivo study; animal model of CRSBI
	5 mg/mL	Heparin 2,500 units/mL	Visual confirmation of physical compatibility up to 72 hours		In vivo study
	5 mg/mL	Heparin 10 units/mL	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions	In vivo study
	0.5 mg/mL	Heparin 100 units/mL	Bioassay stability sampling confirmed ≤ 10% loss at 10 days at 25°C and 37°C in polystyrene test tubes; addition of susceptible bacteria had no impact on stability	Dwell time up to 72 hours between HD sessions	In vitro bioassay stability study
Ceftazidime21–23,86,95,97,98	0.5 mg/mL	Heparin 100 units/mL	Bioassay stability sampling confirmed < 10% loss of activity at 3 days at 25°C and 37°C in polystyrene test tubes; 30%–38% loss of activity at 7 days at 37°C	Dwell time of 8–12 hours/day; duration 7–14 days	In vitro bioassay stability study; in vivo study
	2 mg/mL	Heparin 100 units/mL	Concentrations from aspirated lock after ≤ 15 days and ≤21 days in situ remained 234 μg/mL and 110 μg/mL, respectively	Continuous dwell times of 2–34 days (median =17 days)	In vivo study with residual antibiotic concentration analysis
	2.5 mg/mL	Vancomycin 2.5 mg/mL and heparin 2,500 units/mL	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions	In vivo study
	5 mg/mL	Heparin 2,500 units/mL	Visual confirmation of physical compatibility; authors state up to 72 hours at 37°C (unpublished)	Dwell time up to 72 hours between HD sessions	In vivo study
	10 mg/mL	Heparin 5,000 units/mL	10.6%–12.9% change in absorbance at 48 and 72 hours at 37°C in glass tubes, respectively; 31.9%–40.2% change at 48 and 72 hours in polyurethane catheters, respectively		In vitro stability study
	83.3 mg/mL, 166.6 mg/mL, and 333 mg/mL	No additives		Dwell time of 12 hours daily; average duration of 8 days	Case series
Ceftriaxone86	83.3 mg/mL, 166.6 mg/mL	No additives		Dwell time of 12 hours daily; average duration of 8 days	Case series
Cefotaxime99–104	10 mg/mL	Heparin 5,000 units/mL	Visual confirmation of physical compatibility; one study stored lock solutions under refrigeration prior to instillation in HD port. Chemical/physical stability confirmed at 4°C; > 10% degradation at 24 hours at 27°C and 40°C	Dwell time up to 72 hours between HD sessions	In vivo study; in vitro stability study
Carbapenems
Imipenem/cilastatin29	50 mg/mL	Heparin	Visual confirmation of physical compatibility		In vivo study
Fluoroquinolones
Ciprofloxacin23,29,38,68,95,105,106	0.100 mg/mL	Heparin 5,000 units/mL (reported as 5% heparin sodium)	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions; duration of 15 days	In vivo study
	0.125 mg/mL	Heparin 100 units/mL	Bioassay stability sampling confirmed no loss of activity at 10 days at 25°C and 37°C in polystyrene test tubes; addition of susceptible bacteria had no impact on stability; ciprofloxacin concentrations >0.125 μg/mL formed visual precipitation with heparin		In vitro bioassay stability study
	0.1–1 mg/mL	Heparin 10–10,000 units/mL	Visual stability at 7 days at 25°C and 37°C in glass tubes confirmed for the following combinations: ciprofloxacin 0.1 mg/mL + heparin 10–10,000 units/mL; ciprofloxacin 0.2 mg/mL + heparin 1,000–10,000 units/mL; ciprofloxacin 0.4–0.6 mg/mL + heparin 5,000–10,000 units/mL		In vitro stability study
	0.1–1 mg/mL	Teicoplanin 0.1–4 mg/mL + heparin 7–10,000 units/mL	Visual stability at 7 days at 25°C and 37°C in glass tubes confirmed for the following combinations: teicoplanin 0.1 mg/mL + ciprofloxacin 0.1 mg/mL + heparin 7–10,000 units/mL; teicoplanin 0.2 mg/mL + ciprofloxacin 0.2 mg/mL + heparin 700–10,000 units/mL; teicoplanin 0.4–2.0 mg/mL + ciprofloxacin 0.4 mg/mL + heparin 3,500–10,000 units/mL; teicoplanin 4 mg/mL + ciprofloxacin 0.8 mg/mL + heparin 10,000 units/mL		In vitro stability study
	0.2–0.8 mg/mL	Sodium citrate 22 g/L	Authors report visual stability at 7 days at 25°C and 37°C in glass tubes		In vitro stability study
	0.4–0.6 mg/mL	Teicoplanin 4 mg/mL + sodium citrate 22 g/L	Visual stability confirmed at 7 days at 25°C and 37°C in glass tubes for ciprofloxacin 0.4 mg/mL in combination		In vitro stability study
	1 mg/mL	Heparin 2,500 units/mL	< 10% variability at 72 hours at 37°C in glass tubes		In vitro bioassay stability study
	2 mg/mL	Heparin	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions	In vivo study
	10 mg/mL	No additives	< 10% variability at 10 days at 37°C in glass tubes		In vitro bioassay stability study
	10 mg/mL	Heparin 5,000 units/mL	Immediate precipitation		In vitro stability study
Levofloxacin27,47	0.05, 3.2 mg/mL	Clarithromycin 200 mg/mL ± heparin 1,000 units/mL	Visual confirmation of compatibility at 96 hours at 37°C		In vitro stability and bioactivity study
	5 mg/mL	Heparin 100 units/mL	Precipitation noted; levofloxacin 5 mg/mL used without additive	Dwell time minimum of 12 hours/day, changed daily; Duration of 7–14 days	Case series
Aminoglycosides
Amikacin18,19,38,40,65,66,68,70,88,107–109	0.02–4 mg/mL	Teicoplanin 0.02–10 mg/mL ± heparin 7–10,000 units/mL	Visual stability at 7 days at 25°C and 37°C in glass tubes confirmed for the following combinations: teicoplanin 0.02–0.5 mg/mL + amikacin 0.02–0.05 mg/mL; teicoplanin 0.02–2 mg/mL + amikacin 0.02–3 mg/mL + heparin 700–10,000 units/mL; teicoplanin 4–10 mg/mL + amikacin 0.02–3 mg/mL + heparin 3,000–10,000 units/mL		In vitro stability study
	1 mg/mL	No additives		Dwell time of 24 hours, changed daily; duration of 5 days	In vivo study
	1.5 mg/mL	No additives	Bioactivity reported by authors up to 14 days stored at 4°C	Dwell time 12 hours/day; changed daily; duration of 14 days	In vivo study
	2 mg/mL	No additives		Dwell time of 12 hours/day; changed every 12 hours; duration 10–14 days	Case report
	2 mg/mL	Heparin 20 units/mL	Visual confirmation of physical compatibility	Dwell time minimum of 72 hours; duration of 3–14 days	In vivo study
	5 mg/mL	No additives		Dwell time 12–24 hours; duration 11 days	Case report
	5 mg/mL	Vancomycin 5 mg/mL + heparin 5,000 units/mL	Visual confirmation of physical compatibility	Dwell time of 72 hours; duration of 3 days	In vivo study
	10 mg/mL	Heparin 5,000 units/mL	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions	Case report
	20 mg/mL	No additives		Dwell time 12–24 hours; duration 3 days	In vivo study
	40 mg/mL	Heparin 100 units/mL	Visual confirmation of physical compatibility	Continuous dwell changed every 8 hours; duration of 14 days	In vivo study
Gentamicina,34,38,45,48,63,95,110,111	0.1 mg/mL	Heparin 5,000 units/mL	At 4°C, compatible and stable for up to 4 weeks; confirmed via particle-enhanced turbidimetric inhibition immunoassay		In vitro stability study
	0.32 mg/mL	Citrate 40 mg/mL	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions	In vivo study
	0.02–2 mg/mL	Teicoplanin 0.02–2 mg/mL + heparin 7–10,000 units/mL	At 25°C and 37°C, gentamicin 0.02 and teicoplanin 0.02 compatible at all heparin concentrations; gentamicin 0.2–1 mg/mL, teicoplanin 0.2–1 mg/mL + heparin 3,500–10,000 units/mL compatible for 7 days		In vitro stability and bioactivity study
	1 mg/mL	Heparin 2,500 units/mL + vancomycin 2.5 mg/mL + cefazolin 5 mg/mL	Compatibility confirmed at 37°C for 72 hours	Dwell time up to 72 hours between HD sessions	In vivo study
	2, 4 mg/mL	Teicoplanin 4 mg/mL + citrate 22 g/dL	Gentamicin 2 mg/mL + teicoplanin 4 mg/mL + citrate compatible at 37°C for 7 days		In vitro stability study
	2.5 mg/mL	Heparin 10 units/mL	Visual confirmation of physical compatibility	Dwell time 12–24 hours; duration up to 15 days	Case series
	2.5 mg/mL	Citrate 40 mg/mL	At 37°C, no decrease in gentamicin or citrate concentration at 96 hours; at room temperature, 100% of gentamicin and 101.3% citrate retained for 112 days		In vitro stability studies
	3 mg/mL	Daptomycin 1 mg/mL + citrate 28 mg/mL + LR	Refer to Daptomycin section in this table		In vitro stability study
	5 mg/mL	EDTA 30 mg/mL	Visual confirmation of physical compatibility for 72 hours in glass tubes at 25°C and 37°C	Dwell time 12–24 hours	In vitro bioactivity study; animal model
	5 mg/mL	Heparin 10 units/mL	Visual confirmation of physical compatibility		In vitro bioactivity study
	5 mg/mL	Heparin 1,000 units/mL	Visual confirmation of physical compatibility	Dwell time 12–24 hours; duration up to 15 days	Case series; in vivo study
	5 mg/mL	Heparin 5,000 units/mL	92% of gentamicin concentration retained at 72 hours	Dwell time 12–24 hours; duration up to 15 days	In vitro stability study
	5 mg/mL	Vancomycin 10 mg/mL+ heparin 10–5,000 units/mL	Mild haziness on preparation, dissipated with time and warming	Dwell time 12–24 hours; duration up to 15 days	Case series
Tobramycin20,34,36,112	2.4 mg/mL	Sodium citrate 40 mg/mL	Stability and compatibility confirmed at 48 hours at 23°C and 37°C		In vitro stability study
	5 mg/mL	TPA 0.875 mg/mL	Stability and compatibility confirmed at 12 hours room temperature	Dwell times of 72 hours with HD sessions	In vivo study; case series
	5 mg/mL	TPA 1 mg/mL	Visual confirmation of physical compatibility up to 48 hours		In vivo study
Glycopeptides
Vancomycina,20,22,23,39,40,46,70,95,104,106,107,110,113–121	0.025 mg/mL	Heparin 9.75 units/mL	At 4°C or room temperature, vancomycin concentrations stable for 40 days	Dwell times variable in neonates	In vitro bioassay stability study; in vivo study
	0.025 mg/mL	Heparin 100 units/mL	At 4°C, vancomycin concentration stable for 14 days; at 37°C, concentration reduced by 15%–37% at 24 hours		In vitro stability study; in vivo study
	0.025 mg/mL	Heparin 5,000 units/mL	At 4°C and 27°C, compatible and stable for 72 hours; at 40°C, 81 % of vancomycin concentration retained at 72 hours	Dwell times variable in adult cancer patients	In vitro stability study; in vivo study
	0.1 mg/mL	Heparin 5,000 units/mL	At 4°C, compatible and stable for up to 4 weeks		In vitro stability study
	0.1 mg/mL	Colistin 0.1 mg/mL + heparin 100 units/mL	Refer to Colistin section in this table		In vitro stability study
	0.5 mg/mL	Heparin 100 units/mL	Bioassay stability sampling confirmed < 10% loss of activity at 10 days at 25°C and 37°C in polystyrene test tubes; addition of susceptible bacteria and no impact on stability		In vitro bioassay stability study
	1 mg/mL	No additives	Bioactivity reported by authors up to 14 days stored at 4°C	Dwell time 12 hours/day; changed daily; duration of 14 days	In vivo study
	1 mg/mL	Citrate 40 mg/mL	At 4°C, RT, or 37°C, >92% of vancomycin concentration at 72 hours with storage in polyvinyl chloride syringes of HD catheters		In vitro stability study
	2 mg/mL	Heparin 20 units/mL	Visual confirmation of compatibility; prepared every 3 days and stored at 4°C	Dwell times of 8–12 hours per day; duration of 14 days	In vivo study
	2 mg/mL	Heparin 100 units/mL	Vancomycin concentration of ≥0.130 mg/mL retained for up to 28 days	Dwell time 4–28 days in ports of patients	In vivo studies
	2 mg/mL	Heparin 2,500 units/mL	At 37°C, stable for at least 72 hours and physically compatible; at 37°C, >90% of vancomycin concentration over 72 hours		In vitro stability studies
	2 mg/mL	Citrate 22 mg/mL	Initial precipitation, but no precipitation noted after 10 minutes of incubation at 37°C; >90% of vancomycin concentration over 72 hours		In vitro stability study
	2 mg/mL	Citrate 40 mg/mL	Physically compatible; at 37°C, >90% of vancomycin concentration retained over 72 hours		In vitro stability study
	2.5 mg/mL	Heparin 2.5 units/mL	Decrease in vancomycin concentration gradient from proximal to distal segments of dialysis catheter at 48 hours	Dwell time 48 hours in HD catheters	In vivo study with drug concentration analysis
	3 mg/mL	No additives			In vivo study
	3 mg/mL	Citrate 40 mg/mL	At 4°C, RT, or 37°C, >92% of vancomycin concentration at 72 hours with storage in polyvinyl chloride syringes of HD catheters		In vitro stability study
	5 mg/mL	TPA 1 mg/mL	Visual confirmation of physical compatibility up to 48 hours		In vivo study
	5 mg/mL	No additives		Dwell times of 48 hours; duration of 7 days	In vivo study
	5 mg/mL	Heparin 2,500 units/mL	At 37°C, >90% of vancomycin concentration at 72 hours and physically compatible		In vitro stability study
	5 mg/mL	Citrate 22 mg/mL	Initial precipitation, but no precipitation noted after 10 minutes of incubation at 37°C; >90% of vancomycin concentration over 72 hours		In vitro stability study
	5 mg/mL	Citrate 40 mg/mL	Physically compatible; at 37°C, >90% of vancomycin concentration retained over 72 hours		In vitro stability study
	10 mg/mL	Heparin 5,000 units/mL	In glass test tubes stored at 37°C, no change in vancomycin concentration over 72 hours; in CVCs, concentration decreased by 29.7% over 72 hours		In vitro stability study; in vivo study
	10 mg/mL	Gentamicin 8 mg/mL + heparin 5,000 units/mL	Visual confirmation of physical compatibility	Dwell times up to 72 hours between HD sessions; duration of 2 weeks	In vivo study
Teicoplanin38,122,123	0.02–10 mg/mL	Heparin 10–10,000 units/mL	Visual compatibility confirmed at 7 days at 25°C and 37°C in glass tubes		In vitro stability study
	0.1–4.0 mg/mL	Ciprofloxacin 0.1–1 mg/mL + heparin 7–10,000 units/mL	See ciprofloxacin section		In vitro stability study
	0.02–2.0 mg/mL	Gentamicin 0.02–2 mg/mL + heparin 7–10,000 units/mL	Refer to Gentamicin section in this table		In vitro stability study
	0.02–10 mg/mL	Amikacin 0.02–4 mg/mL + heparin 7–10,000 units/mL	Refer to Amikacin section in this table		In vitro stability study
	4 mg/mL	Ciprofloxacin 0.4–0.6 mg/mL + sodium citrate 22 mg/mL	Refer to Ciprofloxacin section in this table		In vitro stability study
	4 mg/mL	Gentamicin 2–4 mg/mL + sodium citrate 22 mg/mL	Refer to Gentamicin section in this table		In vitro stability study
	10 mg/mL	Heparin 5,000 units/mL	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions; duration of 21 days	In vivo study
Telavancin39	2, 5 mg/mL	Heparin 2,500 units/mL	Physical and chemical stability at 72 hours at 37°C; aPTT increased in 5 mg/mL solution
	2, 5 mg/mL	Citrate 22 mg/mL, 0 mg/mL	Physical and chemical stability at 72 hours at 37°C		In vitro stability study
Oxazolidinones
Linezolid34,37,38,113	0.2–1.92 mg/mL	Heparin 10–10,000 units/mL	Visual compatibility confirmed at 7 days at 25°C and 37°C in glass tubes		In vitro stability study
	1 mg/mL	Citrate 20 mg/mL	Confirmation of physical stability based on visual changes, absorbance, and pH for 48 hours at 23°C and 37°C in glass tubes		In vitro stability study
	2 mg/mL	Heparin 100 units/mL	Visual confirmation of physical compatibility	Dwell time of 8 hours; duration of 20 days	Case report
	2 mg/mL	Heparin 2,000 units/mL	Visual confirmation of physical compatibility	Dwell time up to 72 hours between HD sessions	In vivo study
Lipopeptides
Daptomycin34,45,64,124–127	1 mg/mL	Heparin 5,000 units/mL (reconstituted in 0.9% NS and LR)	Visual compatibility confirmed at 72 hours at 25°C and 37°C in glass tubes		In vitro bioactivity study
	1 mg/mL	Heparin 100–1,000 units/mL	Visual compatibility confirmed for preparation	Dwell times 12–24 hours; duration up to 15 days	In vivo study
	1 mg/mL	Gentamicin 3 mg/mL + citrate 28 mg/mL + LR	At 25°C, 90.7% and 86.7% of daptomycin concentration retained at 48 and 72 hours, respectively; 95.2% of gentamicin concentration retained at 96 hours		In vitro stability study
	2.5 mg/mL	Ethanol 25%	Visual confirmation of physical compatibility		In vitro bioactivity study
	5 mg/mL	Heparin 100 units/mL (reconstituted in LR)	<5% decrease in daptomycin and heparin concentrations at 14 days at 4°C and −20°C in polypropylene syringes		In vitro stability study; in vivo study
	5 mg/mL	Citrate 4% (supplemented with calcium chloride 50 μg/mL)	Confirmation of physical stability based on visual changes, absorbance, and pH for 48 hours at 23°C and 37°C in glass tubes		In vitro stability study
	5 mg/mL, 25 mg/mL	Heparin 5, 5,000, 10,000 units/mL (reconstituted in LR)	< 10% decrease in daptomycin concentration at 24 hours at 37°C		In vitro bioactivity and stability study; in vivo study
Tetracyclines
Minocycline40–42,69,70,128,129	0.2 mg/mL		Bioactivity reported by authors up to 4 days stored at 4°C	Dwell time 12 hours/day; changed daily; duration of 14 days	In vivo study
	2–3 mg/mL	EDTA 30 mg/mL ± ethanol 25%	Visual compatibility confirmed	Dwell times up to 7 days used	In vitro bioactivity study; in vivo study
Glycylcyclines
Tigecycline45,130,131	0.5 mg/mL	EDTA 30 mg/mL	Visual compatibility confirmed at 48 hours at 25°C and 37°C in glass tubes; color change detected after 48 hours		In vitro bioactivity study
	1 mg/mL	NAC 80 mg/mL + heparin 2,000 units/mL (heparin 100 units/mL in single case report)	Visual compatibility confirmed; samples stored at −21°C until use	Dwell times 12–72 hours; duration 14 days	In vivo study; case report
Folate antagonists
Sulfamethoxazole/trimethroprim27,128	10, 16 mg/mL (based on TMP component)	Heparin 100 units/mL	Visual confirmation of physical compatibility for up to 14 days (16 mg/mL solution)		In vivo study
Trimethoprim128,132	5, 10 mg/mL	EDTA 30 mg/mL + ethanol 25% (referred to as “B-lock”)	Visual confirmation of physical compatibility		In vitro bioactivity study
Polymyxins
Colistin46,47	0.1 mg/mL	Vancomycin 0.1 mg/mL + heparin 100 units/mL	Compatibility and stability confirmed; < 10% degradation at 60 days at 4°C and 25°C; vancomycin had ~25% decrease in concentrations after day 15 at room temperature		In vitro stability study
	0.8 mg/mL	Clarithromycin 200 mg/mL ± heparin 1,000 units/mL	Visual confirmation of physical compatibility at 96 hours		In vitro bioactivity study

Note:

Several published reports of gentamicin and vancomycin were not included in the table due to duplication of concentrations.

Abbreviations: aPTT, activated partial thromboplastin time; CRBSI, catheter-related bloodstream infection; CVC, central venous catheter; EDTA, ethylenediaminetetraacetic acid; HD, hemodialysis; LR, lactated ringer's solution; NAC, N-acetylcysteine; NS, normal saline; RT, room temperature; TPA, tissue plasminogen activator; TMP, trimethoprim.

Beta-lactams have been studied extensively in lock solutions. Ampicillin and cefazolin have proven stability and compatibility in combination with heparin at varying concentrations and may offer options for management of susceptible gram-positive pathogens. Cefazolin and tissue plasminogen activator (TPA) have been combined in a lock solution.20 Cefotaxime and ceftazidime have each been studied in combination with heparin, including several clinical studies with ceftazidime-based lock therapy.21,22 Absorption into plastic polymers has been described; yet despite this apparent loss of antibiotic, ceftazidime concentrations expected to be active against biofilm-producing organisms were achieved 21 days postinstillation.22,23 Beta-lactams with extended spectrums including piperacillin, piperacillin/tazobactam, and ticarcillin/clavulanate have also been studied in combination with heparin.23–27 Cefepime has only been investigated in a single in vitro model without additives.28 There is a general lack of data regarding carbapenems in lock solutions. A single clinical study of imipenem/cilastatin in combination with heparin and an unpublished abstract suggesting meropenem and heparin stability and compatibility in a lock solution are available.29,30 More data are needed with carbapenem-based solutions as CRBSI secondary to multi-drug resistant organisms (MDRO) with limited treatment options are certain to increase over time.

Aminoglycosides, specifically amikacin, gentamicin, and tobramycin, have been studied extensively with a number of additives, including heparin, citrate, TPA, and other antimicrobials. Aminoglycosides have proven effectiveness in multiple in vitro models and are among the most commonly utilized solutions in CRBSI prophylaxis. Amikacin in combination with heparin alone and with vancomycin in solution has demonstrated stability. Higher concentrations of amikacin (>10 mg/mL) have been associated with ototoxicity.18 These concentrations pose a significant risk to the patient, especially when flushed into systemic circulation, and should not be utilized in a lock solution. Gentamicin is among the most studied antibiotics in lock solution. Despite the large number of in vitro and in vivo studies, concern remains about its relative compatibility and stability with heparin in solution. Conflicting results in the literature suggest the development of cloudiness or precipitation on preparation of gentamicin plus heparin lock solutions.31 Although this may be a concentration-dependent phenomenon, other factors including the relative volumes of solution components, order of preparation, temperature, and product manufacturers may contribute. Although not extensively evaluated, exposure to higher temperatures (eg, a catheter lumen) and elapsing time have been suggested to improve the solution appearance.31 Data are mostly consistent in reporting compatibility of gentamicin concentrations <4 mg/mL combined with heparin concentrations >1,000 units/mL.32 Alternatively, extended stability >100 days has been demonstrated for gentamicin plus citrate in solution. Citrate-based solutions have shown improved clinical outcomes when compared to heparin-based controls.33 The combination of gentamicin plus citrate should be considered a viable option in both a prophylactic and treatment modality. Tobramycin has also been studied in combination with heparin, citrate, or TPA.20,34–36

Vancomycin in combination with heparin has been evaluated in a number of in vitro and clinical studies. Compatibility with heparin has been consistently demonstrated at vancomycin concentrations <10 mg/mL. Others have reported a visual haze with higher concentrations of vancomycin (>5 mg/mL) in combination with high concentrations of heparin (eg, 5,000 units/mL); however, these appear to be alleviated with slight agitation.31 Vancomycin has also been shown to be compatible in combination with citrate or TPA in solution. The combination of vancomycin plus citrate offers a nonheparinized solution that may be beneficial in many patient populations. Vancomycin has also been combined in solution with other antibiotics including gentamicin with success. As previously described, vancomycin activity against established biofilms is concentration-dependent and has shown to be inferior to comparator agents, including linezolid.37 Although not clearly demonstrated, widespread use of vancomycin in a prophylactic modality may increase the likelihood of developing resistance, and use in this manner should be cautioned. Teicoplanin as an alternative to vancomycin has demonstrated similar compatibility with heparin up to 10,000 units/mL. Varying compatibility has been reported for teicoplanin in combination with citrate and other antimicrobials, including gentamicin and ciprofloxacin.38 Telavancin has shown compatibility with heparin and citrate, however there are no published reports of clinical use.39

Fluoroquinolones, specifically ciprofloxacin and levofloxacin, have been studied in a lock solution. Ciprofloxacin at low concentrations in combination with heparin at low concentrations (≤2,500 units) has demonstrated stability and compatibility. Incompatibilities have been reported with higher concentrations of each component in solution. One study confirmed visual stability of ciprofloxacin and citrate for up to 7 days. Levofloxacin precipitation with heparin has been noted, and published use of levofloxacin in a lock solution is limited. Ciprofloxacin may offer an option for management of gram-negative CRBSI.

Tetracyclines, most commonly minocycline, have been utilized in ALT for nearly 30 years.40 The antibiofilm activity and proposed synergy with ion chelators offer a promising option as a lock solution. Minocycline in combination with the ion chelator, EDTA, has demonstrated visual compatibility in a number of in vitro models and clinical studies. Minocycline plus EDTA has demonstrated effectiveness in preventing CRBSI in pediatric cancer patients and hemodialysis-dependent adults with dwell times up to 7 days.41–44 Doxycycline plus EDTA may be a promising alternative to minocycline. Tetracyclines are not compatible with heparin. The lack of consistent availability of EDTA may limit the use of minocycline-based regimens. Future study with other ion chelators (eg, citrate) is recommended.

Several agents that may be used for resistant gram-positive infections including daptomycin, linezolid, and tigecycline have been studied. Daptomycin has proven stability with heparin and citrate at varying concentrations. Reconstitution of daptomycin with Lactated Ringer’s solution (LR) or supplementation of the lock solution with calcium is required for activity.45 Use with ion chelators, such as citrate, in solution cannot be recommended at this time without confirmation of bioactivity. Linezolid stability with heparin or citrate has been confirmed, although published clinical use is quite limited. Because of the limitations of linezolid therapy in CRBSI, its use as a lock solution should be reserved for very specific cases with limited treatment options. Tigecycline has been studied in combination with N-acetylcysteine (NAC) and heparin in a lock solution with positive clinical outcomes. Concerns with tigecycline use for bloodstream infections should limit its use to specific patient cases as a lock solution.

Many other agents have been studied in a limited manner as lock solutions, including colistimethate, clindamycin, macrolides, sulfamethoxazole/trimethoprim (SMX/TMP), and rifamycins. Data for colistimethate and SMX/TMP are included in Table 2. Stability data for colistimethate and SMX/TMP are limited, but these may be potential options for treatment of CRBSI secondary to MDRO.46 Clindamycin use in a lock solution is limited to a single published study.26 Macrolides have been utilized in lock solutions in combination due to their potential impact on biofilms.47,48 Rifamycins have been studied as in vitro models, primarily in combination with agents such as minocycline and ethanol. Because their use as a primary agent in a lock solution would not be encouraged, they are not discussed in this review.31 Dalbavancin, oritavancin, tedizolid, and ceftaroline are new to the US market and have not been studied in lock solutions.

Non-antibiotic antiseptics, such as ethanol and taurolidine, have also been used in a lock solution. Further, ion chelators (eg, citrate, EDTA) without antibiotics in solution are used in some institutions as the standard lock solution as an alternative to heparin- or saline-based solutions.49,50 Ethanol combinations with antibacterials have been highlighted in this review, and further details of ethanol as a potential lock solution are available elsewhere.14,31 Antifungal agents lack extensive stability and compatibility data, and their use is limited to select clinical cases. Available data are discussed elsewhere.31,51

Logistical challenges and common questions

While ALT represents a valuable option for many patients, relative unfamiliarity with this treatment modality may result in a delay or lack of ALT utilization. In order to optimize clinical outcomes with ALT, clinicians should consider the most common logistical challenges and questions for their practice setting in advance. The development of standardized protocols and/or institution-specific pathways may significantly improve utilization and success with ALT.

Preparation

The first step in considering ALT often requires locating preparation information for the desired antibiotic lock formulation. The development of local evidence-based recipes for pharmacy use along with corresponding order forms for prescriber use should significantly curb confusion surrounding ALT. Standardizing antibiotic concentrations, additives, and product expirations used in local practice should also increase familiarity and minimize the risk of medication errors with ALT. The information summarized herein can serve as a useful tool in developing such materials.

A particularly important additive to consider is the anticoagulant. Any acute changes regarding the addition of an anticoagulant, the specific agent used, and/or the concentration desired at the point of prescribing may render the current stability/compatibility information, and thus the preparation procedure, invalid. Such changes may significantly delay ALT initiation. Therefore, clinicians developing local ALT protocols should consider published evidence, availability of the anticoagulant, and local patient populations (eg, hemodialysis or oncology vs general medicine patients) before selecting a standard antibiotic lock formulation. Oftentimes, providing two or three standard lock formulations for each antibiotic agent may best suit local practice needs, such as one with antibiotic alone and one coformulated with high-concentration heparin (5,000 units/mL) for hemodialysis patients.

While heparin is historically the most common anticoagulant used in catheter locks, there is a growing body of data supporting the use of alternative anticoagulants such as the ion chelators, citrate or EDTA. A recent meta-analysis of 13 randomized controlled trials suggested citrate locks, specifically those coformulated with antibiotics, were superior to heparin locks in preventing CRBSI in patients with hemodialysis catheters (risk ratio [RR]: 0.39, P<0.001).33 Citrate locks were also associated with significantly lower risk of bleeding events compared to heparin locks in this patient population (RR: 0.48, P=0.002), yet outcomes regarding catheter patency were comparable.33 In a 2010 position statement on the management of hemodialysis-CRBSI, the European Renal Best Practice (ERBP) supported ALT to prevent CRBSI and specifically recommended citrate 4% as the preferred agent/concentration.52 The beneficial effects of citrate are likely secondary to its calcium-chelating properties, which confer both antimicrobial and anticoagulant effects.53 The decreased risk of bleeding events is likely secondary to the rapid metabolism of citrate in the bloodstream.33 This latter property is advantageous in the event of the citrate-containing lock being inadvertently flushed into the systemic circulation. There are slightly fewer clinical data regarding the use of EDTA in catheter locks (mainly as preventive ALT in combination with minocycline),41–44 but the results are promising. A clinical study of a minocycline–EDTA lock as adjunctive treatment of CRBSI is currently ongoing.54

The debate over how and when to use anticoagulants in ALT is still evolving; yet, product availability of the alternative agents remains a potential logistical challenge. Availability of EDTA varies significantly by country. The current available formulation in the US is the salt, calcium EDTA 200 mg/mL (also known as calcium disodium versenate).55 Its only US Food and Drug Administration (FDA)-approved indication is the treatment of lead poisoning, meaning use in catheter locks is off-label. An alternative formulation of EDTA, edetate disodium, was removed from the US market in 2008 secondary to fatal errors in adults and children where the two EDTA formulations were confused and the incorrect agent was administered.56 Thus, current use of EDTA as an anticoagulant in ALT may be most appropriate as part of a formal research protocol.

Citrate formulations have also faced safety concerns and suffered from periodic market withdrawals. In 2000, the FDA recommended against use of high concentration citrate (46.7%) as a catheter anticoagulant due to a case of a patient who experienced cardiac arrest, likely secondary to hypocalcemia, following a full-strength injection into a newly placed hemodialysis catheter.57 This formulation was voluntarily recalled in the US at the time and is now solely indicated as an anticoagulant for granulocytapheresis procedures.57 It requires dilution prior to use and direct IV infusion is contraindicated. Additional serious adverse effects associated with high concentrations of citrate lock solutions continue to be reported worldwide.58–60 The FDA currently recommends a lower citrate concentration of 4% for use in catheter locks.61 The ERBP also recommend a citrate 4% solution given its preferable benefit/risk ratio compared to higher concentrations.52 Citrate 4% formulations are available in the US and worldwide, yet many are indicated solely for use in apheresis procedures (like the high-concentration citrate product). In the European Union, formulations of citrate 4% are available with the specific indication for use in CVC, such as a solution of citrate 4% alone (Citra-Lock™; Dirinco AG, Bern, Switzerland) and one of taurolidine–citrate 4% in combination (Taurolock™; Tauro-Implant GmbH, Winsen, Germany).61,62 Lastly, another potential limitation of calcium chelators is the inability to combine them with daptomycin locks until bioactivity of the daptomycin has been confirmed.31,45

Another issue regarding antibiotic lock preparation involves the relative waste of stock antibiotic solutions when only a small amount of an IV product is used to formulate the lock (eg, a daptomycin 500 mg vial used for a 5 mg lock). Standardization of expiration dates may allow for batch preparation of IV antibiotics with antibiotic locks, thereby minimizing product waste. Compliance with USP 797 guidelines for stability and compatibility of antibiotic locks remains somewhat challenging as the majority of current data is based on visual confirmation of physical stability as opposed to higher quality methodology such as high-performance liquid chromatography. However, there are some data suggesting certain antibiotic lock formulations have extended stability, eg, gentamicin 2.5 mg/mL and trisodium citrate 40 mg/mL, which are stable at room temperature for 112 days.63 Such a formulation could be prepared in bulk and/or with IV doses of gentamicin. High cost antibiotics (eg, linezolid, daptomycin) are typically reserved for specific patient scenarios when these agents are selected as the optimal concomitant systemic therapy.

Initiation and duration of therapy

When a CRSBI is suspected, discussion on catheter removal versus salvage is likely to occur as part of an interdisciplinary management decision with the patient and team. If catheter salvage is being considered, even remotely, ALT should also be considered. For treatment of CRBSI, ALT initiation within the first 48–72 hours is associated with enhanced outcomes,20,64 preventing infection-related sequelae and improving the likelihood of catheter salvage. Delays of ALT are often common in practice as the decision to attempt CVC salvage may not be immediately known and other logistical issues discussed herein may prevent a standard protocol from being applicable for every specific case scenario. Nevertheless, active ALT protocols should help prevent treatment delay in a majority of patients.

Duration of ALT is often consistent with that of concurrent systemic therapy. Current guideline recommendations of targeting 10–14 days of ALT are based on limited comparative clinical data.5 Others have proposed abbreviated courses of therapy of 72 hours.65,66 Often the intended duration of therapy may be interrupted or shortened due to transitions of care, especially upon hospital discharge. Early discussions with case management and other personnel are needed to ensure continuation of ALT beyond an inpatient stay, if necessary. Although more data are needed to identify the optimal duration of ALT, abbreviated courses may offer a more convenient, cost-effective option and reduce the risk of resistance.

Dwell time and catheter accessibility

The optimal dwell time for ALT is unclear; however, the majority of clinical studies have proposed a minimum of 8 hours per day, with targets of ≥12 hours per day to achieve optimal sterilization.67,68 Several in vitro models have shown exposure times of approximately 4 hours being effective in reducing bacterial colony counts, but the impact of shortened exposure times is unavailable for many antibiotic–pathogen combinations.45,69 Ideally, the solution may be locked in situ whenever the CVC is not in use. Catheter access often limits the dwell time, especially when the CVC is being used for IV antibiotics and other systemic therapies. The nurse or person responsible for medication administration should be actively engaged to ensure replacement of the lock solution if interruption of the dwell is required.

As alluded to above, the CVC is often being used for additional systemic therapies because it is often the only point of central venous access. Active discussions among the interdisciplinary team, including the patient’s nurse, are required to ensure proper profiling and scheduling of the lock solution. Prior to profiling of the ALT, certain factors should be considered: 1) the number of lumens for the specific CVC and 2) IV therapies scheduled for administration through the CVC (especially any continuous IV infusions). In cases of a multi-lumen CVC, the optimal scenario is to lock all lumens with the antibiotic solution. If a continuous IV fluid is being administered in a patient with multiple lumens, the nurse may be instructed to rotate lumens every 12–24 hours, alternating the lock solution to allow for exposure of each lumen to the ALT. This may present a significant challenge, and proper labeling of CVC lumens can be used to identify a rotation schedule. However, if a significant number of scheduled IV therapies are expected, an attempt should be made to coadminister them wherever possible (based on known compatibility data). Alternatively, holding continuous infusions like fluids or TPN for brief (24–36 hour) periods initially70 or changing the administration to a peripheral IV access may be viable options in select patients.

Risks of antibiotic lock therapy

There are a number of potential and documented risks associated with ALT. As with any solution allowed to dwell in a catheter lumen, the potential for occlusion exists. This risk is expected to be decreased if the solution also contains an anticoagulant. Flushing of the lock solution may expose the patient to unnecessary systemic concentrations of antibiotics and/or anticoagulants – a risk that increases with flushing frequency. Although some systemic exposure from CVC leakage may be expected, the risk of toxicity is likely quite limited if the lock is aspirated as directed. However, high-concentration antibiotic solutions associated with serious toxicities, eg, aminoglycosides and ototoxicity, should still be avoided.18 The greatest risk of flushing is likely in lock solutions containing higher concentrations of anticoagulants, particularly heparin >1,000 units/mL or citrate 30%–46.7%. At these concentrations, the patient may be exposed to systemically active doses that would increase risk of bleeding or hypocalcemia and arrhythmias, respectively.57,71 Low-level exposure of antibiotics may potentially increase the risk of resistance.72,73 However, this concern should be weighed against findings that routine prophylactic use of ALT may reduce the general rate of CRBSI, thereby decreasing overall need for systemic antibiotic therapy.15,33

Conclusion

Given the integral role of long-term CVC use in health care delivery, ALT remains an important option for the preventive and adjunctive treatment of CRBSI. A wide variety of antibiotics have been evaluated for clinical use, with the largest body of data available for vancomycin and gentamicin. In order to ensure optimal clinical outcomes with ALT, clinicians should consider common technical questions and logistical challenges in advance. These include lock preparation procedures, use of additives (eg, heparin, citrate, or EDTA), timing of initiation and therapy duration, dwell time and catheter accessibility, and risks associated with ALT. Development of local protocols is recommended in order to assist clinicians with these potential issues and facilitate utilization of ALT where appropriate.